Genmab
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, USA, and Genmab K.K. in Tokyo, Japan. Genmab is a dual-listed company with shares traded on both the Copenhagen Stock Exchange in Denmark and the NASDAQ Global Select Market in the US.
| Company type | Publicly traded Aktieselskab |
|---|---|
| Nasdaq Copenhagen: GMAB Nasdaq: GMAB (ADR) OMX Copenhagen 25 component | |
| Industry | Biotechnology |
| Founded | 1999 |
| Founder | Florian Schönharting and Lisa Drakeman |
| Headquarters | Copenhagen, Denmark |
Number of locations | 4 (2022) |
Key people |
|
| Products | DARZALEX/ DARZALEX FASPRO EPKINLY/TEPKINLY Kesimpta RYBREVANT TALVEY TECVAYLI TEPEZZA Tivdak |
| Revenue | DKK 14.595 billion (2022) |
| DKK 6.357 billion (2022) | |
| DKK 5.522 billion (2022) | |
Number of employees | 1,660 (2022) |
| Website | Genmab.com |
The company has 8 approved antibodies (monoclonal and bispecific) used in 8 marketed products, covering cancer indications and autoimmune diseases.
Proprietary, marketed with partners:
- Epkinly/Tepkinly (epcoritamab) for the treatment of Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) (AbbVie)
- Tivdak (tisotumab vedotin) for the treatment of previously treated recurrent or metastatic cervical cancer (Seagen)
Marketed by partners:
- Darzalex (IV) (daratumumab) / Darzalex Faspro (SC) (daratumumab and hyaluronidase) for the treatment of all stages of multiple myeloma as combination therapy or monotherapy, and for the treatment of newly diagnosed amyloid light-chain (AL) amyloidosis (Janssen)
- Kesimpta (ofatumumab) for the treatment of relapsing remitting multiple sclerosis (Novartis)
- Rybrevant (amivantamab) for the treatment of non-small-cell lung cancer (EGFR exon 20 insertion mutations) (Janssen)
- Talvey (talquetamab) for the treatment of relapsed/refractory MM (Janssen)
- Tecvayli (teclistamab) for the treatment of relapsed/refractory MM (Janssen)
- Tepezza (teprotumumab) for the treatment of thyroid eye disease (Horizon)
Furthermore both Genmab and its partners have a whole range of antibody programs, building on Genmab technologies, in clinical and pre-clinical development in both cancer and autoimmune diseases.
Genmab have several late stage clinical programs for tisotumab vedotin (cervical cancer, ovarian cancer and solid tumors) and epcoritamab (B-cell non-Hodgkin lymphoma and Relapsed/refractory Follicular lymphoma).
The partners have, among others, clinical programs for daratumumab (non-MM blood cancers), amivantamab (gastric cancer and esophageal cancer), Mim8 (Factor VIII mimetic bi-specific antibody) (Haemophilia A), inclacumab (VOC in Sickle cell disease) and teprotumumab (diffuse cutaneous systemic sclerosis).